X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EP262 is a potent, highly selective once-daily small molecule antagonist of MRGPRX2, a receptor expressed on mast cells that is activated by numerous ligands, including many peptides released from sensory neurons as well as other cell types.
Lead Product(s): EP262
Therapeutic Area: Immunology Product Name: EP262
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
EP262 is a potent, highly selective small molecule antagonist of MRGPRX2, a receptor mediating non-IgE driven mast cell degranulation. By blocking activation of MRGPRX2 and degranulation of mast cells, it effectively treat Chronic Inducible Urticaria.
Lead Product(s): EP262
Therapeutic Area: Dermatology Product Name: EP262
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
EP262 is a potent, highly selective small molecule antagonist of MRGPRX2, a receptor mediating non-IgE driven mast cell degranulation. By blocking activation of MRGPRX2 and degranulation of mast cells, it effectively treat a broad range of mast cell mediated diseases.
Lead Product(s): EP262
Therapeutic Area: Dermatology Product Name: EP262
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
EP262 is a potent, highly selective small molecule antagonist of MRGPRX2, a receptor mediating non-IgE driven mast cell degranulation. By blocking activation of MRGPRX2 and degranulation of mast cells, it effectively treat a broad range of mast cell mediated diseases.
Lead Product(s): EP262
Therapeutic Area: Dermatology Product Name: EP262
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
EP262, a potent, highly selective antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), represents a novel, targeted approach to the treatment of mast cell-mediated disorders.
Lead Product(s): EP262
Therapeutic Area: Dermatology Product Name: EP262
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
Proceeds from the financing will be used to advance the company’s pipeline of two first-in-class product candidates in several indications.
Lead Product(s): EP547
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: EP547
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NEA
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 28, 2022
Details:
EP547 is highly selective antagonist of MRGPRX4, cell surface receptor expressed on sensory neurons that is activated by bile acids, bilirubin and other heme metabolites and thought key mediator of often intense itch experienced by patients with cholestatic liver disease.
Lead Product(s): EP547
Therapeutic Area: Dermatology Product Name: EP547
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Proceeds support clinical development for lead program in cholestatic and uremic pruritus and second program for mast cell-related diseases.
Lead Product(s): EP547
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: EP547
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Sanofi Ventures
Deal Size: $77.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
